Playback speed
10 seconds
ESMO 2023 Insights: "Omission of Breast Surgery After Neoadjuvant Systemic Therapy for Invasive Cancer - 3-Year Preplanned Primary-Endpoint on a Phase 2 Multicentre Prospective Trial"
By
Insights from 2023 ESMO Annual Meeting
FEATURING
Henry Kuerer
By
Insights from 2023 ESMO Annual Meeting
FEATURING
Henry Kuerer
647 views
October 26, 2023
Comments 1
Login to view comments.
Click here to Login
Recommended
AUTOPLAY